Literature DB >> 17594388

The lean patient with type 2 diabetes: characteristics and therapy challenge.

Brunetti P1.   

Abstract

Although obesity is a key component of type 2 diabetes, particularly in the Western world, many patients are not overweight by traditional criteria. However, evolving definitions of overweight and obesity and an appreciation of the factors influencing obesity in type 2 diabetes are redefining the concept of the non-overweight (lean) patient. Several factors need to be considered, including body mass index, waist circumference and ethnicity when considering whether a patient is lean, and appropriate obesity threshold values need to be used. Lean patients are more likely to be older at diagnosis, possibly have an immune component and may have a tendency towards certain pathophysiological characteristics, notably less insulin resistance and poorer insulin secretory capacity. However, pathophysiological heterogeneity may also be greater among lean patients and this imparts a particular challenge to therapy. An early focus on multiple metabolic defects may provide an optimal approach to treating the lean patient with type 2 diabetes in clinical practice, and combination therapy that addresses both insulin secretory dysfunction and insulin resistance would seem a rational approach.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17594388     DOI: 10.1111/j.1742-1241.2007.01359.x

Source DB:  PubMed          Journal:  Int J Clin Pract Suppl        ISSN: 1368-504X


  20 in total

1.  A mini-network balance model for evaluating the progression of cardiovascular complications in Goto-Kakizaki rats.

Authors:  Hao Jiang; Yu-Hao Wang; Chun-Xiang Wei; Xue Zhang; Hao-Chen Liu; Xiao-Quan Liu
Journal:  Acta Pharmacol Sin       Date:  2017-01-02       Impact factor: 6.150

2.  Functional, metabolic, and morphologic characteristics of a novel rat model of type 2 diabetes-associated erectile dysfunction.

Authors:  Maarten Albersen; Guiting Lin; Thomas M Fandel; Haiyang Zhang; Xuefeng Qiu; Ching-Shwun Lin; Tom F Lue
Journal:  Urology       Date:  2011-05-31       Impact factor: 2.649

Review 3.  Cardiovascular, renal and overall health outcomes after bariatric surgery.

Authors:  Ji C Tham; Carel W le Roux; Neil G Docherty
Journal:  Curr Cardiol Rep       Date:  2015-05       Impact factor: 2.931

4.  Differential muscle gene expression as a function of disease progression in Goto-Kakizaki diabetic rats.

Authors:  Jing Nie; Bai Xue; Siddharth Sukumaran; William J Jusko; Debra C Dubois; Richard R Almon
Journal:  Mol Cell Endocrinol       Date:  2011-02-26       Impact factor: 4.102

Review 5.  The role of bariatric surgery in the treatment of diabetes.

Authors:  Ji Chung Tham; Noah Howes; Carel W le Roux
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 6.  The role of gut microbiota in the development of type 1, type 2 diabetes mellitus and obesity.

Authors:  Ningwen Tai; F Susan Wong; Li Wen
Journal:  Rev Endocr Metab Disord       Date:  2015-03       Impact factor: 6.514

Review 7.  Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management.

Authors:  S Del Prato; J LaSalle; S Matthaei; C J Bailey
Journal:  Int J Clin Pract       Date:  2010-02       Impact factor: 2.503

8.  Hexarelin, a Growth Hormone Secretagogue, Improves Lipid Metabolic Aberrations in Nonobese Insulin-Resistant Male MKR Mice.

Authors:  Rasha Mosa; Lili Huang; Yeda Wu; Chungyan Fung; Oshini Mallawakankanamalage; Derek LeRoith; Chen Chen
Journal:  Endocrinology       Date:  2017-10-01       Impact factor: 4.736

9.  Body weight and its influence on hepcidin levels in patients with type 2 diabetes: A systematic review and meta-analysis of clinical studies.

Authors:  Fransina Ndevahoma; Munyaradzi Mukesi; Phiwayinkosi V Dludla; Bongani B Nkambule; Elina P Nepolo; Tawanda M Nyambuya
Journal:  Heliyon       Date:  2021-03-11

10.  Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo.

Authors:  Yoshiharu Horie; Naoyuki Hayashi; Klaus Dugi; Masahiro Takeuchi
Journal:  Trials       Date:  2009-09-05       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.